The efficacy of early bispecific antibodies redirecting T-cells to eradicate cancer cells was partly limited because of suboptimal effector cell engagement [1] . More efficient T-cell activation has been obtained with single-chain variable fragment (scFv) antibodies, notably bispecific T-cell engagers (BiTEs) [2] . Activity of the CD19/CD3 BiTE blinatumomab in adults and children with chemotherapyresistant CD19+ B-cell acute lymphoblastic leukemia (B-ALL) led to regulatory drug approval in Europe and the United States. Many other BiTEs, all relying on CD3 signaling without providing co-stimulation, are in clinical testing in several solid tumors and hematologic malignancies [2, 3] .
The experience with blinatumomab demonstrates many patients fail BiTE therapy for poorly-understood reasons despite target antigen expression on their cancer cells [4, 5] . Recent data from our group and others have shown that expression of CD80 or CD86, which signal through CD28, on cancer cells increases BiTE-induced cytotoxicity in vitro, [6, 7] as does co-treatment with a monoclonal CD28 antibody [6] . These data suggest the importance of co-receptor activation for maximal anti-tumor efficacy of BiTEs, a finding reminiscent of data obtained with T-cells expressing chimeric antigen receptors (CARs), when significant improvements in potency were achieved after inclusion of co-stimulatory signaling moieties in the CAR constructs. Since non-specific, cancer cell-independent boosting of CD28-mediated co-stimulation can lead to overwhelming cytokine production, as shown with the superagonist antibody TGN1412 [8] , we envisioned a novel immunotherapeutic approach built on two BiTEs (or "Simultaneous multiple interaction T-cell engaging [SMITE] bispecifics"; Fig. 1a ), each of which binds cancer cells and either CD3 or CD28 to provide T-cell costimulation when employed together in the presence of the target antigen-expressing cancer.
To develop our platform, we generated a series of CD3directed and CD28-directed bispecific antibodies targeting the cancer cell-associated antigens CD19 and receptor tyrosine kinase-like orphan receptor 1 (ROR1) [9] as well as a CD28-directed bispecific antibody targeting PD-L1. Briefly (see Online Supplement for detailed methods), we used variable domain sequences available from the literature ( Supplementary Table 1 ) for CD19 (blinatumomab), ROR1 (clone R12), CD3 (blinatumomab), CD28 (TGN1412), and PD-L1 (atezolizumab) to build molecules in the canonical BiTE format ( Supplementary Fig. 1a ). Protein sequences were reverse-translated using human codons and cloned into a modified pCVL lentiviral vector which was then used to transduce Freestyle TM 293-F cells. Secreted protein was extracted from the conditioned media via immobilized metal-affinity chromatography and subsequently polished Fig. 1b-d) . Fractions corresponding to the monomeric proteins were pooled, quantitated, and further analyzed by SDS-PAGE ( Supplementary Fig. 1b-d , insets). As source for T-cells, unstimulated peripheral blood mononuclear cells were collected from healthy adult volunteers via leukapheresis under research protocols approved by the Fred Hutch Institutional Review Board after written informed consent was obtained. T-cells were enriched via negative selection through magnetic cell sorting (Pan T-Cell Isolation Kit; Miltenyi Biotec, Auburn, CA, USA), and stored in aliquots in liquid nitrogen [10] . Thawed cell aliquots were used, unlabeled or labeled with CellVue dye (eBioscience, San Diego, CA, USA), in assays without prior pre-stimulation [6, [10] [11] [12] . To obtain well-controlled experimental models, sublines of human myeloid K562 and human lymphoid CD19+ RCH-ACV and REH cells overexpressing ROR1 were generated through transduction with a pMP71 retrovirus (kindly provided by Dr. Stanley R. Riddell, Fred Hutchinson Cancer Research Center, Seattle, WA). Sublines of cells overexpressing PD-L1 were generated through transduction with a pRRLsin.cPPT.MSCV lentivirus [11, 13, 14] containing a human PD-L1-IRES-Enhanced Green Fluorescent Protein cassette [6] . To quantify T-cell activation, target antigen-negative and target antigen-positive cancer cells were labeled with CellVue dye and incubated in 96-well plates together with unlabeled healthy-donor T-cells at an effector:target (E:T) ratio of 1:1. Unlike antibodies to CD3 and CD28, which can dimerize targets, BiTEs like those we generated will depend upon cancer cell binding to engage and co-activate T-cells because the CD3 and CD28 binding is monovalent and occurs via two separate molecules, avoiding unwanted immune stimulation. This feature is exemplified with human K562 cells engineered to express ROR1 and parental ROR1-cells ( Fig. 1b) , in which healthy-donor T-cell activation by a ROR1/CD3 BiTE, as estimated by cell surface expression of CD69 and CD25, and co-activation by a ROR1/CD28 BiTE (i.e., left-hand scheme depicted in Fig. 1a ) is dependent on ROR1 display on cancer cells. In contrast, monoclonal CD3 antibody (clone OKT3) activates T-cells independent of ROR1 expression. Likewise, as long as T-cells are stimulated via CD3, monoclonal CD28 antibody (clone CD28.2) provides T-cell co-activation to both ROR+ and ROR1-K562 cells.
Consistent with the data on T-cell activation, CD28 BiTEs were ineffective alone but significantly augmented the cytotoxic effects of CD3 BiTEs in a dose-dependent fashion ( Fig. 1c [for ROR1] and Supplementary Fig. 2 [for CD19]), resulting in maximal cell killing at much lower antibody doses in combination than what could be accomplished with CD3 BiTE alone. Significant enhancement of CD3 BiTE-induced cancer cell killing was also found when the CD28 BiTE was directed at a second cancer cellassociated antigen (i.e., right-hand scheme depicted in Fig. 1a ), as shown in Fig. 1d and Supplementary Fig. 3 , allowing for the selective targeting of cancers expressing two independent antigens. The magnitude of this effect was similar to that achieved with a CD28 antibody (Fig. 1e) , although direct comparisons are limited by the fact that the antibody sequence used in the CD28 BiTE differed from the monoclonal CD28 antibody we had available for our studies.
Because two different cancer cell antigens can be targeted with SMITE bispecific pairs, we tested the ability of this immunotherapy approach to overcome inhibitory T-cell signaling. Of particular interest is PD-L1 ( Fig. 2a) , which we and others identified as a ligand conferring resistance to CD3 BiTEs in mechanistic studies in vitro [6, 7, 15] . Consistent with this notion, PD-L1 was found to be increased on B-ALL cells of patients refractory to blinatumomab [7] . Given this data, we investigated the potential of a PD-L1/CD28 BiTE to overcome PD-L1-mediated drug resistance. Although PD-L1 may be too widely expressed to target with a direct toxin like an antibody-drug conjugate, the requirement for CD3 costimulation with a SMITE bispecific approach allows PD-L1 to be considered as one of the two targeted cancer antigens. Similar to the other CD28directed bispecific molecules we studied, T-cell co-activation with the PD-L1/CD28 BiTE was strictly dependent on the expression of PD-L1 target antigen and the engagement of CD3 with CD19/CD3 (Fig. 2b) . Consistent with these Tcell activation data, co-treatment with a PD-L1/CD28 BiTE did not affect CD19/CD3 BiTE-induced cytotoxicity in parental, PD-L1-negative CD19+ B-ALL cells. However, this BiTE not only reversed the relative PD-L1-mediated resistance in paired cells expressing PD-L1 but led to increased cytotoxic effects relative to parental cells treated with CD19/CD3 BiTE antibody alone (Fig. 2c) . Thus, the PD-L1/CD28 BiTE undermined PD-L1, not only blocking its immunosuppressive signal but converting it into a potent costimulatory one.
In summary, our data indicate CD28 BiTEs can potently co-activate T cells stimulated with a CD3 BiTE at concentrations where either agent is inactive (or minimally active) alone, and the strict requirement for the presence of target antigen(s) suggests the possibility for both high selectivity and potency. Such pairs of bispecific antibodies can conceptually target any cancer cell surface antigen(s) and will thus provide a versatile platform exploitable for a wide variety of cancers. As our studies demonstrate, pairs of BiTEs can be utilized to neutralize a cellular resistance factor such as checkpoint inhibition and reverse it into Tcell co-activation for optimized therapeutic efficacy. While our studies focused on CD28, demonstrating that signaling via CD28 is a key modulator of the therapeutic efficacy of BiTE antibodies, future efforts will develop SMITE bispecific pairs targeting other co-receptor signaling pathways. After 48 h, drug-induced cytotoxicity was determined by flow cytometry. Increases in the percentage of DAPI-positive cells in BiTEtreated cells are compared with corresponding cells that were incubated without antibody, and results are shown as mean ± SEM from three independent experiments performed in duplicate wells. Throughout, two-sided P values were calculated using repeated measure one-way or two-way ANOVA with Tukey's multiple comparison test as appropriate. For all panels, *P < 0.05, † P < 0.01, ‡ P < 0.001, and § P < 0.0001 vs. corresponding control Current response criteria for evaluating hematologic response in light chain (AL) amyloidosis do not require a bone marrow examination to evaluate for residual plasma cells [1] . Complete response (CR) is defined as achieving a normal free light chain (FLC) ratio and negative immunofixation in serum and urine. In a study of multiple myeloma patients [2] , 10% of patients achieving all the serum criteria for stringent CR by conventional International Myeloma Working Group (IMWG) response criteria [3] had increased plasma cells in the bone marrow. Moreover, patients who had less than 5% plasma cells in the marrow had better outcomes, thereby reinforcing the importance of bone marrow biopsy in response evaluation in multiple myeloma. More recently, it has been demonstrated than achieving even deeper responses with minimal residual disease (MRD) negativity is associated with superior survival outcomes in multiple myeloma [4, 5] . Recent work from our institution in AL amyloidosis found that in patients achieving a very good partial response, those with less than 0.1% monotypic plasma cells in the bone marrow on six color multi-parametric flow cytometry displayed a trend towards better PFS [6] .
The objective of our study was to evaluate if bone marrow biopsy findings provide additional prognostic value in patients with AL amyloidosis who achieve a CR by current response criteria.
Following IRB approval, we identified 80 patients with newly diagnosed AL amyloidosis from 2006-2015, who achieved a CR with therapy as defined above and concomitantly underwent a bone marrow biopsy. All patients had given written informed consent for review of their medical records for research. Bone marrow examination included a morphological evaluation of the aspirate and core biopsy for assessment of plasma cells in all patients, as well as flow cytometry in 78 of 80 patients to identify clonality 
